# CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

Study · id `cardio:ct-nct05422534` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05422534](<https://clinicaltrials.gov/study/NCT05422534>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05422534

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 156 participants.

## Technical summary

Registry record NCT05422534. Randomized; double masking; primary purpose prevention. Start 2023-06-01 (actual); primary completion 2027-06-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 156 participants (planned count; ClinicalTrials.gov record NCT05422534, source copy `cardio:ctgov-nct05422534-2026-01-02`, retrieved 2026-10-26)
- Started: 2023-06-01 (actual) (ClinicalTrials.gov record NCT05422534, source copy `cardio:ctgov-nct05422534-2026-01-02`, retrieved 2026-10-26)
- Primary completion: 2027-06-20 (anticipated) (ClinicalTrials.gov record NCT05422534, source copy `cardio:ctgov-nct05422534-2026-01-02`, retrieved 2026-10-26)
- Completion: 2027-10-01 (anticipated) (ClinicalTrials.gov record NCT05422534, source copy `cardio:ctgov-nct05422534-2026-01-02`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05422534, source copy `cardio:ctgov-nct05422534-2026-01-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05422534-2026-01-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
- Condition: End Stage Renal Disease
- Intervention (Dietary supplement): CoQ10
- Intervention (Drug): Placebo
- Intervention (Behavioral): HB-HIIT
- Intervention (Behavioral): Observational
- Lead sponsor: Vanderbilt University Medical Center
- Lead sponsor class: OTHER
- Collaborator: University of California, Davis
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Vanderbilt University Medical Center (`cardio:org-vanderbilt-university-medical-center`)
- Registry lists this organization as a collaborator: University of California, Davis (`cardio:org-university-of-california-davis`)

## Provenance

Content hash: 1ea70b8fa8490e05f69d77ae1115e569b0ec8b4879aa8bd32e4b47a1482dfd49
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
